Shots:
- Madrigal has entered into an exclusive global license agreement with Pfizer for ervogastat (PF-06865571; PO) to treat metabolic dysfunction-associated steatohepatitis (MASH)
- As per the deal, Madrigal will receive an exclusive global license to develop, manufacture & commercialize ervogastat & 2 additional early-stage MASH assets, paying Pfizer $50M upfront with further milestone payments & net sales-based royalties
- In a published P-II trial, ervogastat (150mg) reduced liver fat by ≥30% & ≥50% in 72% & 61% of pts, respectively, with improvements in liver enzymes & stiffness. In 2026, Madrigal plans a drug–drug interaction study with Rezdiffra & FDA discussions on a P-II combination trial design
Ref: Globenewswire | Image: Madrigal & Pfizer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
